CJC-1295 No DAC 3mg + Ipamorelin 3mg + Sermorelin 6mg: Product & Research Information

Overview

CJC-1295 No DAC 3mg + Ipamorelin 3mg + Sermorelin 6mg is a three-peptide combination described by its labeled composition. The ingredients are associated with scientific research into growth hormone signaling, endocrine physiology, and the mechanisms that regulate pituitary hormone release.

The stated formulation contains 3 mg of CJC-1295 No DAC, 3 mg of ipamorelin, and 6 mg of sermorelin, for a total labeled peptide content of 12 mg per vial. These quantities reflect the product labeling and do not independently verify the vial’s contents, purity, or quality.

Understanding the Three Peptides

CJC-1295 No DAC

CJC-1295 is a synthetic peptide associated with growth hormone-releasing hormone (GHRH) signaling. The term “No DAC” generally distinguishes a shorter-acting, non-DAC form from versions designed with a drug-affinity complex that prolongs activity.

The naming of CJC-1295 without DAC can be inconsistent across commercial sources and may overlap with terminology such as modified GRF (1-29). Exact chemical identity should therefore be established from reliable product documentation rather than the label alone.

Research into CJC-related compounds has examined their effects on growth hormone signaling. However, clinical evidence is limited, and the compound is not an FDA-approved medicine.

Ipamorelin

Ipamorelin is a synthetic peptide investigated as a growth hormone secretagogue. It acts through the ghrelin receptor, also known as GHS-R1a, which participates in signaling pathways involved in growth hormone release.

Although ipamorelin has been studied in experimental settings, its biological activity does not establish the safety or effectiveness of unapproved products for muscle development, fat loss, recovery, or anti-aging purposes.

The FDA has identified concerns about certain compounded ipamorelin products, including potential immunogenicity associated with peptide aggregation or impurities and insufficient safety information for certain routes of administration.

Sermorelin

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone. It has been investigated for its ability to stimulate the pituitary gland to release growth hormone.

Sermorelin is associated with the GHRH signaling pathway, which differs from ipamorelin’s ghrelin-receptor pathway. Its inclusion in a combination does not establish that the blend offers additional benefits or a predictable hormonal response.

Research Context for the Combination

The three ingredients are associated with pathways involved in growth hormone regulation, but they have distinct pharmacological properties.

Research into individual peptides cannot establish the safety, effectiveness, pharmacokinetics, or appropriate clinical use of this specific three-peptide combination. Evidence would need to address the actual formulation and its intended use.

Claims that this combination reliably increases muscle mass, reduces body fat, improves sleep, accelerates recovery, or reverses aging should not be treated as established clinical outcomes without adequate evidence specific to the blend.

Safety and Regulatory Considerations

Growth hormone signaling is involved in multiple physiological processes, and altering this system may have unintended effects. Potential concerns include changes in glucose regulation, fluid retention, and abnormal growth signaling. The risks associated with a specific product depend on its composition, formulation, exposure, and the individual using it.

The FDA has identified potential immunogenicity risks and complexities involving peptide impurities and characterization for CJC-1295. The agency has also identified safety uncertainties for certain compounded ipamorelin formulations and routes of administration.

Neither the research history of an individual ingredient nor the combination of several peptides establishes that the finished vial is safe or effective. The regulatory status of a particular product must be evaluated separately according to its formulation, intended use, and jurisdiction.

Product Documentation

Where genuine documentation is available, relevant information may include the chemical identity of each ingredient, batch-specific analytical results, impurity profiles, and the identity and qualifications of the testing laboratory.

Documentation should correspond to the actual batch and finished formulation. A certificate of analysis or stated purity percentage does not, on its own, establish sterility, suitability for human administration, clinical effectiveness, or regulatory approval.

Important Notice

This page provides general scientific and educational information. It is not medical advice or a treatment recommendation. The safety and effectiveness of the CJC-1295 No DAC 3mg + Ipamorelin 3mg + Sermorelin 6mg combination have not been established simply by research into its individual ingredients. Consult a qualified healthcare professional regarding questions about growth hormone regulation or endocrine health.

CJC-1295 No DAC 3mg

CJC-1295 NO-DAC 3mg + Ipa 3mg + Sermorelin 6mg.